Clinical Trial Detail

NCT ID NCT01526473
Title A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors H. Kim Lyerly
Indications

gastric adenocarcinoma

Advanced Solid Tumor

Her2-receptor positive breast cancer

gastroesophageal junction adenocarcinoma

esophagus adenocarcinoma

Therapies

AVX901

Age Groups: adult

Additional content available in CKB BOOST